Literature DB >> 23574634

Ketamine and peripheral inflammation.

Marc De Kock1, Sebastien Loix, Patricia Lavand'homme.   

Abstract

The old anesthetic ketamine has demonstrated interactions with the inflammatory response. This review intends to qualify the nature and the mechanism underlying this interaction. For this purpose, preclinical data will be presented starting with the initial works, and then, the probable mechanisms will be discussed. A summary of the most relevant clinical data will be presented. In conclusion, ketamine appears as a unique "homeostatic regulator" of the acute inflammatory reaction and the stress-induced immune disturbances. This is of some interest at a moment when the short- and long-term deleterious consequences of inadequate inflammatory reactions are increasingly reported. Large-scale studies showing improved patient's outcome are, however, required before to definitively assert the clinical reality of this positive effect.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574634      PMCID: PMC6493703          DOI: 10.1111/cns.12104

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  105 in total

1.  Ketamine does not inhibit inflammatory responses of cultured human endothelial cells but reduces chemotactic activation of neutrophils.

Authors:  S Zahler; B Heindl; B F Becker
Journal:  Acta Anaesthesiol Scand       Date:  1999-11       Impact factor: 2.105

2.  Ketamine modulates the stimulated adhesion molecule expression on human neutrophils in vitro.

Authors:  M A Weigand; H Schmidt; Q Zhao; K Plaschke; E Martin; H J Bardenheuer
Journal:  Anesth Analg       Date:  2000-01       Impact factor: 5.108

3.  'Balanced analgesia' in the perioperative period: is there a place for ketamine?

Authors:  Marc De Kock; Patricia Lavand'homme; Hilde Waterloos
Journal:  Pain       Date:  2001-06       Impact factor: 6.961

4.  Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood.

Authors:  C Kawasaki; T Kawasaki; M Ogata; K Nandate; A Shigematsu
Journal:  Can J Anaesth       Date:  2001-09       Impact factor: 5.063

5.  Lipid mediator class switching during acute inflammation: signals in resolution.

Authors:  B D Levy; C B Clish; B Schmidt; K Gronert; C N Serhan
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

6.  Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro.

Authors:  T Kawasaki; M Ogata; C Kawasaki; J Ogata; Y Inoue; A Shigematsu
Journal:  Anesth Analg       Date:  1999-09       Impact factor: 5.108

7.  Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine.

Authors:  E Célèrier; C Rivat; Y Jun; J P Laulin; A Larcher; P Reynier; G Simonnet
Journal:  Anesthesiology       Date:  2000-02       Impact factor: 7.892

8.  Ketamine suppresses endotoxin-induced NF-kappaB expression.

Authors:  T Sakai; T Ichiyama; C W Whitten; A H Giesecke; J M Lipton
Journal:  Can J Anaesth       Date:  2000-10       Impact factor: 5.063

9.  Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial.

Authors:  N Hergovich; E Singer; E Agneter; H G Eichler; U Graselli; C Simhandl; B Jilma
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

10.  Ketamine inhibits endotoxin-induced shock in rats.

Authors:  T Taniguchi; K Shibata; K Yamamoto
Journal:  Anesthesiology       Date:  2001-10       Impact factor: 7.892

View more
  54 in total

Review 1.  Pain after knee arthroplasty: an unresolved issue.

Authors:  Irina Grosu; Patricia Lavand'homme; Emmanuel Thienpont
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-11-08       Impact factor: 4.342

Review 2.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

3.  Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Floyd F Steele; Kenner C Rice; Katherine L Nicholson; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

4.  Microglia Polarization and Endoplasmic Reticulum Stress in Chronic Social Defeat Stress Induced Depression Mouse.

Authors:  Jie Tang; Wenbo Yu; Sheng Chen; Zidan Gao; Baoguo Xiao
Journal:  Neurochem Res       Date:  2018-03-24       Impact factor: 3.996

Review 5.  Ketamine use in current clinical practice.

Authors:  Mei Gao; Damoon Rejaei; Hong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-03-28       Impact factor: 6.150

6.  Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress.

Authors:  Helena M Abelaira; Gislaine Z Réus; Zuleide M Ignácio; Maria Augusta B Dos Santos; Airam B de Moura; Danyela Matos; Júlia P Demo; Júlia B I da Silva; Lucineia G Danielski; Fabricia Petronilho; André F Carvalho; João Quevedo
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

7.  Antidepressant effects of moxidectin, an antiparasitic drug, in a rat model of depression.

Authors:  Bruk Getachew; Yousef Tizabi
Journal:  Behav Brain Res       Date:  2019-09-09       Impact factor: 3.332

Review 8.  Duality of Antidepressants and Neuroprotectants.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2015-11-27       Impact factor: 3.911

Review 9.  Neuroimmune mechanisms of depression.

Authors:  Georgia E Hodes; Veronika Kana; Caroline Menard; Miriam Merad; Scott J Russo
Journal:  Nat Neurosci       Date:  2015-09-25       Impact factor: 24.884

Review 10.  Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

Authors:  Rayan K Al Jurdi; Alan Swann; Sanjay J Mathew
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.